3-iodobenzylguanidine has been researched along with Cell Transformation, Neoplastic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Babich, JW; Boyd, M; Mairs, RJ; Rae, C; Sorensen, A; Tesson, M | 1 |
| Boyd, M; Braidwood, L; Brown, M; Conner, J; Joyce, C; Mairs, RJ; Pimlott, S; Sorensen, A | 1 |
2 other study(ies) available for 3-iodobenzylguanidine and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
The role of copper in disulfiram-induced toxicity and radiosensitization of cancer cells.
Topics: 3-Iodobenzylguanidine; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Copper; Disulfiram; Dose-Response Relationship, Drug; Female; Gamma Rays; Humans; Mice; Radiation Tolerance; Spheroids, Cellular | 2013 |
In vivo evaluation of a cancer therapy strategy combining HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.
Topics: 3-Iodobenzylguanidine; Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Combined Modality Therapy; DNA, Recombinant; Gene Transfer Techniques; Glioma; Herpesvirus 1, Human; Humans; Mice; Molecular Targeted Therapy; Norepinephrine Plasma Membrane Transport Proteins; Oncolytic Viruses; Sequence Deletion; Time Factors | 2012 |